Valeriana officinalis attenuates the rotenone-induced toxicity in Drosophila melanogaster

In this study, we investigated the potential protective effects of Valeriana officinalis ( V. officinalis ) against the toxicity induced by rotenone in Drosophila melanogaster ( D. melanogaster ). Adult wild-type flies were concomitantly exposed to rotenone (500 m M) and V. officinalis aqueous extract (10 mg/mL) in the food during 7 days. Rotenone-fed flies had a worse performance in the negative geotaxis assay ( i

[1]  T. Cassano,et al.  Novel codrugs with GABAergic activity for dopamine delivery in the brain. , 2012, International journal of pharmaceutics.

[2]  Muralidhara,et al.  Propensity of Selaginella delicatula aqueous extract to offset rotenone-induced oxidative dysfunctions and neurotoxicity in Drosophila melanogaster: Implications for Parkinson's disease. , 2012, Neurotoxicology.

[3]  C. Tanner,et al.  Solvent exposures and parkinson disease risk in twins , 2012, Annals of neurology.

[4]  J. Pagonabarraga,et al.  Withdrawal of visual feedback in essential tremor. , 2012, Parkinsonism & related disorders.

[5]  C. Cunha,et al.  Behavioral, Neurochemical and Histological Alterations Promoted by Bilateral Intranigral Rotenone Administration: A New Approach for an Old Neurotoxin , 2011, Neurotoxicity Research.

[6]  S. Kügler,et al.  Glutathione depletion and overproduction both initiate degeneration of nigral dopaminergic neurons , 2010, Acta Neuropathologica.

[7]  Lisa M. Del Valle-Mojica,et al.  Aqueous and Ethanolic Valeriana officinalis Extracts Change the Binding of Ligands to Glutamate Receptors , 2010, Evidence-based complementary and alternative medicine : eCAM.

[8]  F. Hirth.  Drosophila melanogaster in the Study of Human Neurodegeneration , 2010, CNS & neurological disorders drug targets.

[9]  Muralidhara,et al.  Neuroprotective efficacy of Bacopa monnieri against rotenone induced oxidative stress and neurotoxicity in Drosophila melanogaster. , 2009, Neurotoxicology.

[10]  R. Gross,et al.  Environmental toxins and Parkinson's disease: what have we learned from pesticide-induced animal models? , 2009, Trends in pharmacological sciences.

[11]  F. Soares,et al.  In vitro Antioxidant Activity of Valeriana officinalis Against Different Neurotoxic Agents , 2009, Neurochemical Research.

[12]  Werner Paulus,et al.  Drosophila melanogaster as a Model Organism of Brain Diseases , 2009, International journal of molecular sciences.

[13]  G. Barreto,et al.  Cytoprotective Effect of Valeriana officinalis Extract on an In Vitro Experimental Model of Parkinson Disease , 2009, Neurochemical Research.

[14]  C. Noe,et al.  Transport of a GABAA receptor modulator and its derivatives from Valeriana officinalis L. s. l. across an in vitro cell culture model of the blood-brain barrier. , 2008, Planta medica.

[15]  A. El‐Solh,et al.  Pharmacotherapy of insomnia , 2008, Expert opinion on pharmacotherapy.

[16]  K. Nieber,et al.  Modulation of postsynaptic potentials in rat cortical neurons by valerian extracts macerated with different alcohols: involvement of adenosine A1‐ and GABAA‐receptors , 2007, Phytotherapy research : PTR.

[17]  M. Norenberg,et al.  The mitochondrial permeability transition in neurologic disease , 2007, Neurochemistry International.

[18]  C. Nichols,et al.  Drosophila melanogaster neurobiology, neuropharmacology, and how the fly can inform central nervous system drug discovery. , 2006, Pharmacology & therapeutics.

[19]  J. Ortiz,et al.  Commercial valerian interactions with [3H]Flunitrazepam and [3H]MK‐801 binding to rat synaptic membranes , 2006, Phytotherapy research : PTR.

[20]  A. Whitworth,et al.  Drosophila models pioneer a new approach to drug discovery for Parkinson's disease. , 2006, Drug discovery today.

[21]  M. Brand,et al.  The topology of superoxide production by complex III and glycerol 3-phosphate dehydrogenase in Drosophila mitochondria. , 2005, Biochimica et biophysica acta.

[22]  C. Suñol,et al.  Excitotoxic death induced by released glutamate in depolarized primary cultures of mouse cerebellar granule cells is dependent on GABAA receptors and niflumic acid‐sensitive chloride channels , 2005, The European journal of neuroscience.

[23]  S. Birman,et al.  Chronic Exposure to Rotenone Models Sporadic Parkinson's Disease in Drosophila melanogaster , 2004, The Journal of Neuroscience.

[24]  W. Neckameyer,et al.  GABAergic modulation of motor-driven behaviors in juvenile Drosophila and evidence for a nonbehavioral role for GABA transport. , 2004, Journal of neurobiology.

[25]  L. Partridge,et al.  Superoxide and hydrogen peroxide production by Drosophila mitochondria. , 2003, Free radical biology & medicine.

[26]  Todd B. Sherer,et al.  An In Vitro Model of Parkinson's Disease: Linking Mitochondrial Impairment to Altered α-Synuclein Metabolism and Oxidative Damage , 2002, The Journal of Neuroscience.

[27]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[28]  W. Bender,et al.  A Drosophila model of Parkinson's disease , 2000, Nature.

[29]  S. W. Davies,et al.  Filamentous nerve cell inclusions in neurodegenerative diseases , 1998, Current Opinion in Neurobiology.

[30]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[31]  G. Ellman,et al.  Tissue sulfhydryl groups. , 1959, Archives of biochemistry and biophysics.

[32]  F. Bodman.  VALERIAN , 1928 .

[33]  M. Rand,et al.  Drosophotoxicology: the growing potential for Drosophila in neurotoxicology. , 2010, Neurotoxicology and teratology.

[34]  J. T. Greenamyre,et al.  Neurotoxic in vivo models of Parkinson's disease recent advances. , 2010, Progress in brain research.

[35]  E. Loreto,et al.  Diphenyl diselenide [(PhSe)2] inhibits Drosophila melanogaster delta-aminolevulinate dehydratase (delta-ALA-D) gene transcription and enzyme activity. , 2008, Comparative biochemistry and physiology. Toxicology & pharmacology : CBP.

[36]  D. Leibfritz,et al.  Free radicals and antioxidants in normal physiological functions and human disease. , 2007, The international journal of biochemistry & cell biology.

[37]  A. Rajput,et al.  Old age and Parkinson's disease. , 2007, Handbook of clinical neurology.

[38]  J. Malva,et al.  Neuroprotective properties of Valeriana officinalis extracts. , 2004, Neurotoxicity research.